SCHEMBL8290253

SCHEMBL8290253

Cc1ccc(C(=O)O)c(=O)n1C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAAO P46952 1/20 0.46
MYC P01106 11/20 0.41
CTSB P07858 2/20 0.41
KLKB1 P03952 1/20 0.41
ELANE P08246 1/20 0.41
MMP9 P14780 1/20 0.41
DUSP3 P51452 1/20 0.41
NR4A1 P22736 5/20 0.41
POLB P06746 3/20 0.40
RECQL P46063 3/20 0.40
TDP1 Q9NUW8 3/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 2/20 0.40
KMT2A Q03164 2/20 0.40
ESR2 Q92731 1/20 0.40
LMNA P02545 1/20 0.38
NOTUM Q6P988 1/20 0.38
KDM4E B2RXH2 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3336282 0.78 TSHR (0.47) POLBMEN1MAPTKMT2ALMNA
SCHEMBL12168771 0.75 HAAO (0.50) HAAOMYCCTSBKLKB1ELANE
SCHEMBL3336907 0.74 KDM4E (0.42) POLBRECQLLMNANOTUMKDM4E
SCHEMBL13303071 0.74 LMNA (0.42) POLBRECQLTDP1MEN1MAPT
SCHEMBL29287248 0.73 HAAO (0.48) HAAOMYCCTSBKLKB1ELANE
SCHEMBL19692164 0.73 NOTUM (0.42) HAAOMYCNR4A1POLBRECQL
SCHEMBL11637724 0.71 ALDH1A1 (0.45) HAAOMYCCTSBKLKB1ELANE
SCHEMBL27669547 0.70 HAAO (0.46) HAAOMYCCTSBKLKB1ELANE
SCHEMBL14969090 0.70 KMT2A (0.43) POLBRECQLMEN1MAPTKMT2A
SCHEMBL3336263 0.70 NOTUM (0.39) MYCCTSBNR4A1POLBRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062416-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS INC (US) 2026-03-05 US disclosed
WO-2024035950-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-02-15 WO disclosed
WO-2024035950-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-02-15 WO disclosed
EP-1713797-B1 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY PFIZER (US) 2008-03-05 EP disclosed
WO-2005073222-A1 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY PFIZER JAPAN, INC. (JP) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062416-A1 INHIBITORS OF KIF18A AND USES THEREOF KIF18A, KIF18B, KIF5B HAAO 3470/4885MYC 3000/4885CTSB 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.